CompletedPhase 2NCT05625477
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers
Studying Tetanus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Principal Investigator
- Jie Hou, MSPeking University Care Luzhong Hospital
- Intervention
- TNM002 (low dose)(biological)
- Enrollment
- 240 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2022
Study locations (4)
- The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
- Wuxi People's Hospital, Wuxi, Jiangsu, China
- PKUCare Luzhong Hospital, Zibo, Shandong, China
- Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, Yunnan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05625477 on ClinicalTrials.govOther trials for Tetanus
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07149454Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody InjectionLanzhou Institute of Biological Products Co., Ltd
- RECRUITINGNCT07107932A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following InjuryZhuhai Trinomab Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06635798A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 InjectionGenrix (Shanghai) Biopharmaceutical Co., Ltd.